APO Research
Talk to an analyst

APO RESEARCH · REPORT

End Stage Renal Disease

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global End Stage Renal Disease Market Outlook and Growth Opportunities 2026

29 December 2025204 pages

Choose your research edition.

Industry ResearchEnd Stage Renal Disease Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal End Stage Renal Disease Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal End Stage Renal Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal End Stage Renal Disease Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal End Stage Renal Disease Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global End Stage Renal Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for End Stage Renal Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for End Stage Renal Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for End Stage Renal Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the End Stage Renal Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the End Stage Renal Disease market include Newsol, Baxter, Guangdong Biolight, B. Braun, DaVita, Fresenius, Jafron Biomedical, Medtronic and Mayo Clinic, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global End Stage Renal Disease market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of End Stage Renal Disease and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents End Stage Renal Disease revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global End Stage Renal Disease market.

End Stage Renal Disease Segment by Company

Newsol

Baxter

Guangdong Biolight

B. Braun

DaVita

Fresenius

Jafron Biomedical

Medtronic

Mayo Clinic

Nipro

Nikkiso

Sanxin Medtec

SWS Hemodialysis Care

Tianyi Medical

WEGO

Asahi Kasei

End Stage Renal Disease Segment by Type

Hemodialysis

Kidney Transplantation

Peritoneal Dialysis

End Stage Renal Disease Segment by Application

At Homes

Kidney Dialysis Centers

Hospitals

Others

End Stage Renal Disease Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global End Stage Renal Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the End Stage Renal Disease key companies, revenue, market share, and recent developments.

3. To split the End Stage Renal Disease breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions End Stage Renal Disease market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify End Stage Renal Disease significant trends, drivers, influence factors in global and regions.

6. To analyze End Stage Renal Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global End Stage Renal Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of End Stage Renal Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of End Stage Renal Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global End Stage Renal Disease industry.

Chapter 3: Detailed analysis of End Stage Renal Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of End Stage Renal Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of End Stage Renal Disease in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. End Stage Renal Disease Industry Trends Table 2. End Stage Renal Disease Industry Drivers Table 3. End Stage Renal Disease Industry Opportunities and Challenges Table 4. End Stage Renal Disease Industry Restraints Table 5. Global End Stage Renal Disease Revenue by Company (US$ Million) & (2021-2026) Table 6. Global End Stage Renal Disease Revenue Share by Company (2021-2026) Table 7. Global End Stage Renal Disease Company Ranking, (2024-2026) & (US$ Million) Table 8. Global End Stage Renal Disease Key Company Manufacturing Base & Headquarters Table 9. Global End Stage Renal Disease Company, Product Type & Application Table 10. Global End Stage Renal Disease Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global End Stage Renal Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hemodialysis Table 15. Significant Companies of Kidney Transplantation Table 16. Significant Companies of Peritoneal Dialysis Table 17. Global End Stage Renal Disease Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global End Stage Renal Disease Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global End Stage Renal Disease Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global End Stage Renal Disease Sales Value Share by Type (2021-2026) Table 21. Global End Stage Renal Disease Sales Value Share by Type (2027-2032) Table 22. Significant Companies of At Homes Table 23. Significant Companies of Kidney Dialysis Centers Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Others Table 26. Global End Stage Renal Disease Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global End Stage Renal Disease Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global End Stage Renal Disease Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global End Stage Renal Disease Sales Value Share by Application (2021-2026) Table 30. Global End Stage Renal Disease Sales Value Share by Application (2027-2032) Table 31. Global End Stage Renal Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global End Stage Renal Disease Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global End Stage Renal Disease Sales Value Share by Region (2021-2026) Table 34. Global End Stage Renal Disease Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global End Stage Renal Disease Sales Value Share by Region (2027-2032) Table 36. Global End Stage Renal Disease Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global End Stage Renal Disease Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global End Stage Renal Disease Sales Value Market Share by Country (2021-2026) Table 39. Global End Stage Renal Disease Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global End Stage Renal Disease Sales Value Market Share by Country (2027-2032) Table 41. Newsol Company Information Table 42. Newsol Business Overview Table 43. Newsol End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Newsol End Stage Renal Disease Product Portfolio Table 45. Newsol Recent Development Table 46. Baxter Company Information Table 47. Baxter Business Overview Table 48. Baxter End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Baxter End Stage Renal Disease Product Portfolio Table 50. Baxter Recent Development Table 51. Guangdong Biolight Company Information Table 52. Guangdong Biolight Business Overview Table 53. Guangdong Biolight End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Guangdong Biolight End Stage Renal Disease Product Portfolio Table 55. Guangdong Biolight Recent Development Table 56. B. Braun Company Information Table 57. B. Braun Business Overview Table 58. B. Braun End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. B. Braun End Stage Renal Disease Product Portfolio Table 60. B. Braun Recent Development Table 61. DaVita Company Information Table 62. DaVita Business Overview Table 63. DaVita End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. DaVita End Stage Renal Disease Product Portfolio Table 65. DaVita Recent Development Table 66. Fresenius Company Information Table 67. Fresenius Business Overview Table 68. Fresenius End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Fresenius End Stage Renal Disease Product Portfolio Table 70. Fresenius Recent Development Table 71. Jafron Biomedical Company Information Table 72. Jafron Biomedical Business Overview Table 73. Jafron Biomedical End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Jafron Biomedical End Stage Renal Disease Product Portfolio Table 75. Jafron Biomedical Recent Development Table 76. Medtronic Company Information Table 77. Medtronic Business Overview Table 78. Medtronic End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Medtronic End Stage Renal Disease Product Portfolio Table 80. Medtronic Recent Development Table 81. Mayo Clinic Company Information Table 82. Mayo Clinic Business Overview Table 83. Mayo Clinic End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Mayo Clinic End Stage Renal Disease Product Portfolio Table 85. Mayo Clinic Recent Development Table 86. Nipro Company Information Table 87. Nipro Business Overview Table 88. Nipro End Stage Renal Disease Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Nipro End Stage Renal Disease Product Portfolio Table 90. Nipro Recent Development Table 91. Nikkiso Company Information Table 92. Nikkiso Business Overview Table 93. Nikkiso End Stage Renal Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Nikkiso End Stage Renal Disease Product Portfolio Table 95. Nikkiso Recent Development Table 96. Sanxin Medtec Company Information Table 97. Sanxin Medtec Business Overview Table 98. Sanxin Medtec End Stage Renal Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Sanxin Medtec End Stage Renal Disease Product Portfolio Table 100. Sanxin Medtec Recent Development Table 101. SWS Hemodialysis Care Company Information Table 102. SWS Hemodialysis Care Business Overview Table 103. SWS Hemodialysis Care End Stage Renal Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. SWS Hemodialysis Care End Stage Renal Disease Product Portfolio Table 105. SWS Hemodialysis Care Recent Development Table 106. Tianyi Medical Company Information Table 107. Tianyi Medical Business Overview Table 108. Tianyi Medical End Stage Renal Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Tianyi Medical End Stage Renal Disease Product Portfolio Table 110. Tianyi Medical Recent Development Table 111. WEGO Company Information Table 112. WEGO Business Overview Table 113. WEGO End Stage Renal Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. WEGO End Stage Renal Disease Product Portfolio Table 115. WEGO Recent Development Table 116. Asahi Kasei Company Information Table 117. Asahi Kasei Business Overview Table 118. Asahi Kasei End Stage Renal Disease Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Asahi Kasei End Stage Renal Disease Product Portfolio Table 120. Asahi Kasei Recent Development Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. End Stage Renal Disease Product Image Figure 2. Global End Stage Renal Disease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global End Stage Renal Disease Market Size (2021-2032) & (US$ Million) Figure 4. Global End Stage Renal Disease Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hemodialysis Image Figure 8. Kidney Transplantation Image Figure 9. Peritoneal Dialysis Image Figure 10. Global End Stage Renal Disease Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global End Stage Renal Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global End Stage Renal Disease Sales Value Share by Type (2021-2032) Figure 13. At Homes Image Figure 14. Kidney Dialysis Centers Image Figure 15. Hospitals Image Figure 16. Others Image Figure 17. Global End Stage Renal Disease Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global End Stage Renal Disease Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global End Stage Renal Disease Sales Value Share by Application (2021-2032) Figure 20. Global End Stage Renal Disease Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global End Stage Renal Disease Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America End Stage Renal Disease Sales Value (2021-2032) & (US$ Million) Figure 23. North America End Stage Renal Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe End Stage Renal Disease Sales Value (2021-2032) & (US$ Million) Figure 25. Europe End Stage Renal Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific End Stage Renal Disease Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific End Stage Renal Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America End Stage Renal Disease Sales Value (2021-2032) & (US$ Million) Figure 29. South America End Stage Renal Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa End Stage Renal Disease Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa End Stage Renal Disease Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt End Stage Renal Disease Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Hemodialysis
  • Kidney Transplantation
  • Peritoneal Dialysis
Applications
  • At Homes
  • Kidney Dialysis Centers
  • Hospitals
  • Others
Companies covered
  • Newsol
  • Baxter
  • Guangdong Biolight
  • B. Braun
  • DaVita
  • Fresenius
  • Jafron Biomedical
  • Medtronic
  • Mayo Clinic
  • Nipro
  • Nikkiso
  • Sanxin Medtec
  • SWS Hemodialysis Care
  • Tianyi Medical
  • WEGO
  • Asahi Kasei

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global End Stage Renal Disease Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global End Stage Renal Disease Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 End Stage Renal Disease Market Dynamics
  1. 2.1 End Stage Renal Disease Industry Trends
  2. 2.2 End Stage Renal Disease Industry Drivers
  3. 2.3 End Stage Renal Disease Industry Opportunities and Challenges
  4. 2.4 End Stage Renal Disease Industry Restraints
3 End Stage Renal Disease Market by Company
  1. 3.1 Global End Stage Renal Disease Company Revenue Ranking in 2025
  2. 3.2 Global End Stage Renal Disease Revenue by Company (2021-2026)
  3. 3.3 Global End Stage Renal Disease Company Ranking (2024-2026)
  4. 3.4 Global End Stage Renal Disease Company Manufacturing Base and Headquarters
  5. 3.5 Global End Stage Renal Disease Company Product Type and Application
  6. 3.6 Global End Stage Renal Disease Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global End Stage Renal Disease Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 End Stage Renal Disease Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 End Stage Renal Disease Market by Type
  1. 4.1 End Stage Renal Disease Type Introduction
  2. 4.1.1 Hemodialysis
  3. 4.1.2 Kidney Transplantation
  4. 4.1.3 Peritoneal Dialysis
  5. 4.2 Global End Stage Renal Disease Sales Value by Type
  6. 4.2.1 Global End Stage Renal Disease Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global End Stage Renal Disease Sales Value by Type (2021-2032)
  8. 4.2.3 Global End Stage Renal Disease Sales Value Share by Type (2021-2032)
5 End Stage Renal Disease Market by Application
  1. 5.1 End Stage Renal Disease Application Introduction
  2. 5.1.1 At Homes
  3. 5.1.2 Kidney Dialysis Centers
  4. 5.1.3 Hospitals
  5. 5.1.4 Others
  6. 5.2 Global End Stage Renal Disease Sales Value by Application
  7. 5.2.1 Global End Stage Renal Disease Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global End Stage Renal Disease Sales Value by Application (2021-2032)
  9. 5.2.3 Global End Stage Renal Disease Sales Value Share by Application (2021-2032)
6 End Stage Renal Disease Regional Value Analysis
  1. 6.1 Global End Stage Renal Disease Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global End Stage Renal Disease Sales Value by Region (2021-2032)
  3. 6.2.1 Global End Stage Renal Disease Sales Value by Region: 2021-2026
  4. 6.2.2 Global End Stage Renal Disease Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America End Stage Renal Disease Sales Value (2021-2032)
  7. 6.3.2 North America End Stage Renal Disease Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe End Stage Renal Disease Sales Value (2021-2032)
  10. 6.4.2 Europe End Stage Renal Disease Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific End Stage Renal Disease Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific End Stage Renal Disease Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America End Stage Renal Disease Sales Value (2021-2032)
  16. 6.6.2 South America End Stage Renal Disease Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa End Stage Renal Disease Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa End Stage Renal Disease Sales Value Share by Country, 2025 VS 2032
7 End Stage Renal Disease Country-level Value Analysis
  1. 7.1 Global End Stage Renal Disease Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global End Stage Renal Disease Sales Value by Country (2021-2032)
  3. 7.2.1 Global End Stage Renal Disease Sales Value by Country (2021-2026)
  4. 7.2.2 Global End Stage Renal Disease Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt End Stage Renal Disease Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt End Stage Renal Disease Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt End Stage Renal Disease Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Newsol
  2. 8.1.1 Newsol Company Information
  3. 8.1.2 Newsol Business Overview
  4. 8.1.3 Newsol End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Newsol End Stage Renal Disease Product Portfolio
  6. 8.1.5 Newsol Recent Developments
  7. 8.2 Baxter
  8. 8.2.1 Baxter Company Information
  9. 8.2.2 Baxter Business Overview
  10. 8.2.3 Baxter End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Baxter End Stage Renal Disease Product Portfolio
  12. 8.2.5 Baxter Recent Developments
  13. 8.3 Guangdong Biolight
  14. 8.3.1 Guangdong Biolight Company Information
  15. 8.3.2 Guangdong Biolight Business Overview
  16. 8.3.3 Guangdong Biolight End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Guangdong Biolight End Stage Renal Disease Product Portfolio
  18. 8.3.5 Guangdong Biolight Recent Developments
  19. 8.4 B. Braun
  20. 8.4.1 B. Braun Company Information
  21. 8.4.2 B. Braun Business Overview
  22. 8.4.3 B. Braun End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  23. 8.4.4 B. Braun End Stage Renal Disease Product Portfolio
  24. 8.4.5 B. Braun Recent Developments
  25. 8.5 DaVita
  26. 8.5.1 DaVita Company Information
  27. 8.5.2 DaVita Business Overview
  28. 8.5.3 DaVita End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  29. 8.5.4 DaVita End Stage Renal Disease Product Portfolio
  30. 8.5.5 DaVita Recent Developments
  31. 8.6 Fresenius
  32. 8.6.1 Fresenius Company Information
  33. 8.6.2 Fresenius Business Overview
  34. 8.6.3 Fresenius End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fresenius End Stage Renal Disease Product Portfolio
  36. 8.6.5 Fresenius Recent Developments
  37. 8.7 Jafron Biomedical
  38. 8.7.1 Jafron Biomedical Company Information
  39. 8.7.2 Jafron Biomedical Business Overview
  40. 8.7.3 Jafron Biomedical End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jafron Biomedical End Stage Renal Disease Product Portfolio
  42. 8.7.5 Jafron Biomedical Recent Developments
  43. 8.8 Medtronic
  44. 8.8.1 Medtronic Company Information
  45. 8.8.2 Medtronic Business Overview
  46. 8.8.3 Medtronic End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Medtronic End Stage Renal Disease Product Portfolio
  48. 8.8.5 Medtronic Recent Developments
  49. 8.9 Mayo Clinic
  50. 8.9.1 Mayo Clinic Company Information
  51. 8.9.2 Mayo Clinic Business Overview
  52. 8.9.3 Mayo Clinic End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mayo Clinic End Stage Renal Disease Product Portfolio
  54. 8.9.5 Mayo Clinic Recent Developments
  55. 8.10 Nipro
  56. 8.10.1 Nipro Company Information
  57. 8.10.2 Nipro Business Overview
  58. 8.10.3 Nipro End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nipro End Stage Renal Disease Product Portfolio
  60. 8.10.5 Nipro Recent Developments
  61. 8.11 Nikkiso
  62. 8.11.1 Nikkiso Company Information
  63. 8.11.2 Nikkiso Business Overview
  64. 8.11.3 Nikkiso End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nikkiso End Stage Renal Disease Product Portfolio
  66. 8.11.5 Nikkiso Recent Developments
  67. 8.12 Sanxin Medtec
  68. 8.12.1 Sanxin Medtec Company Information
  69. 8.12.2 Sanxin Medtec Business Overview
  70. 8.12.3 Sanxin Medtec End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanxin Medtec End Stage Renal Disease Product Portfolio
  72. 8.12.5 Sanxin Medtec Recent Developments
  73. 8.13 SWS Hemodialysis Care
  74. 8.13.1 SWS Hemodialysis Care Company Information
  75. 8.13.2 SWS Hemodialysis Care Business Overview
  76. 8.13.3 SWS Hemodialysis Care End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  77. 8.13.4 SWS Hemodialysis Care End Stage Renal Disease Product Portfolio
  78. 8.13.5 SWS Hemodialysis Care Recent Developments
  79. 8.14 Tianyi Medical
  80. 8.14.1 Tianyi Medical Company Information
  81. 8.14.2 Tianyi Medical Business Overview
  82. 8.14.3 Tianyi Medical End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Tianyi Medical End Stage Renal Disease Product Portfolio
  84. 8.14.5 Tianyi Medical Recent Developments
  85. 8.15 WEGO
  86. 8.15.1 WEGO Company Information
  87. 8.15.2 WEGO Business Overview
  88. 8.15.3 WEGO End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  89. 8.15.4 WEGO End Stage Renal Disease Product Portfolio
  90. 8.15.5 WEGO Recent Developments
  91. 8.16 Asahi Kasei
  92. 8.16.1 Asahi Kasei Company Information
  93. 8.16.2 Asahi Kasei Business Overview
  94. 8.16.3 Asahi Kasei End Stage Renal Disease Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Asahi Kasei End Stage Renal Disease Product Portfolio
  96. 8.16.5 Asahi Kasei Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst